Pharvaris

Pharvaris is a late-stage company advancing novel bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. $PHVS

[Pharvaris @pharvaris]

Thank you @US_HAEA for partnering with us on your latest HAE Speaks Podcast series about the impact of #HAE, the role of #bradykinin in causing an attack, and the current landscape. Listen here: https://t.co/q7mssUgDRd

[Pharvaris @pharvaris]

Today we announced the FDA has accepted our #NDA for investigational #deucrictibant, a novel, potent, orally bioavailable small molecule #BradykininB2 receptor antagonist for the #OnDemand treatment of #HAE attacks in people 12 years and older. See more: https://t.co/ZphBw7jtZB

[Pharvaris @pharvaris]

At Pharvaris, #MedicalAffairs bridges science and patient impact by translating complex clinical data into meaningful insights and medical communication. By collaborating across the AE-BK community we ensure evidence, materials, and tactics serve patients: https://t.co/r2B0asiCO5

[Pharvaris @pharvaris]

Today we shared a summary of data presented at #EAACICongress2026 on our investigational oral #BradykininB2Receptor antagonist for the #prophylactic and #OnDemand treatment of #BradykininMediatedAngioedema attacks. Read more here: https://t.co/72dqmgEtEE

[Pharvaris @pharvaris]

Are you attending #WODCUSA? Our Vice President, Head of Evidence & Outcomes Research, Joan Mendivil, will be presenting insights on, “From Symptoms to Decisions: How Patient-Reported Outcomes Shape Trustworthy Clinical Evidence”, on June 11, at 2pm ET: https://t.co/DdnSn8Chay

[Pharvaris @pharvaris]

Pharvaris will be at #EAACI2026 and is looking forward to connecting with the Allergy and Immunology community around this year’s theme, “Vision Zero: A Future Free from Allergy and Asthma Burden.” Visit our medical booth, number 13. Learn more: https://t.co/6gtUrWoLr6

[Pharvaris @pharvaris]

Today, we announced the acceptance of eight #BradykininMediatedAngioedema abstracts, including one for oral presentation and seven for flash talk/poster presentation, at #EAACI2026 to be held from June 12-15, 2026, in Istanbul, Turkey. Learn more here: https://t.co/KDxR36DIB6

[Pharvaris @pharvaris]

“Ensuring rigor & diversity of thought” is one of the values we are driven by. Our values drive our passion to help meet unmet treatment needs for people living with #BradykininMediatedAngioedema. Meet three Pharvarians who exemplify this value. See more: https://t.co/KA2eujgJ54

[Pharvaris @pharvaris]

Pharvaris’ clinical development journey continues into Phase 3 through the investigation of oral treatment options for #BradykininMediatedDiseases. Our #ClinicalOperations team delivers timely, high-quality data with our passion for operational excellence: https://t.co/Aaq3VLpQBr

[Pharvaris @pharvaris]

To help raise awareness of #HAE, Pharvarians came together and showed their support by going purple and getting #active4HAE. Pharvaris is committed to the community on hae day :-) — and every day. Learn more: https://t.co/URtZHYDTsD

[Pharvaris @pharvaris]

#Pharvarians recently connected with the pharmacy and healthcare community, in #DC and at #AXS26, to discuss the future of #PrescriptionAccess—and Pharvaris’ role within it as we build out our business infrastructure: https://t.co/w7NaBIt3nS

[Pharvaris @pharvaris]

Today, we announced financial results for 1Q26 and provided a business update, including anticipated timing for Ph 3 topline CHAPTER-3 data, on-demand NDA submission timeline, enrollment in CREAATE Ph 3 trial, and cash runway. See here: https://t.co/ShRqNQSFmK

[Pharvaris @pharvaris]

We are pleased to announce the successful closing of our underwritten offering, which raised gross proceeds of $132.3 million. Read more in our press release here: https://t.co/omzekq7MAw

[Pharvaris @pharvaris]

Congratulations to our newly promoted #Pharvarians on your well‑earned milestone. Your passion and commitment drive our mission to advance oral bradykinin B2 receptor antagonists for people living with #BradykininMediatedDiseases. Learn more about us here: https://t.co/UtL9TLNXVc

[Pharvaris @pharvaris]

Pharvaris presented data at the #CIICConference evaluating safety margins of administration of #deucrictibant #ExtendedRelease tablet in combination with deucrictibant #ImmediateRelease capsule(s). Read about the data presented here: https://t.co/IcKKul0lng

[Pharvaris @pharvaris]

We announced our 4Q/YE25 financial results and business update: enrollment in CHAPTER‑3 is complete with topline data anticipated in 3Q26; enrollment in CREAATE is ongoing; #OnDemand NDA submission is on track in 1H26; and our cash position was updated: https://t.co/TJqOMoVYgB

[Pharvaris @pharvaris]

.@TheLancetHaem has published results from the CHAPTER-1 #Phase2 and RAPIDe-1 #Phase2 trials evaluating #deucrictibant, our investigational oral drug for the prophylactic and on-demand treatment of #HereditaryAngioedemaattacks. Read more here: https://t.co/T4U0IhAub5

[Pharvaris @pharvaris]

Are you attending Informa’s #HubEast2026? Don’t miss our Vice President, Access, Trade & Patient Services, Todd Hudson, who will be taking part in a Roundtable, “Navigating Industry Headwinds and Seizing Opportunities”, on March 17, at 2p.m. ET. See more: https://t.co/xNw5BOZDPu

[Pharvaris @pharvaris]

.@Springer_Med’s Clinical Reviews in Allergy & Immunology has published our mixed-methods study evaluating patient experience of acute #HAE attack manifestations and what can constitute meaningful change. Read about the study, and its findings, here: https://t.co/MH8eJKYbQy

[Pharvaris @pharvaris]

Today we shared a summary of data presented at #AAAAI26 on our investigational drug, #deucrictibant. The data demonstrate a potentially differentiated profile for the #prophylactic and #OnDemand treatment of #BradykininMediatedAngioedema attacks. See here: https://t.co/TNpaReZYXD